Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788)
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Health - Bowyer Oncology Center — Los Angeles, California
- UC Irvine Health Chao Family Comprehensive Cancer Center — Orange, California
- University of California San Francisco — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
- Emory Healthcare - The Emory Clinic — Atlanta, Georgia
- Georgia Cancer Center at Augusta University — Augusta, Georgia
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Simmons Cancer Institute — Springfield, Illinois
- University of Iowa Hospitals & Clinics — Iowa City, Iowa
- The University of Kansas Cancer Center — Kansas City, Kansas
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- Washington University School of Medicine — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Northwell Health, LLC PRIME — Lake Success, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical College-NY Presbyterian Hospital — New York, New York
- Wilmot Cancer Institute, University of Rochester — Rochester, New York
📞 Contact the Study Coordinator
Phone: 844-KURAONC (844-587-2662)
Email: medinfo@kuraoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML
- ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial — Houston, Texas
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant — Rochester, New York
- A Long Term Follow-up Study of TScan TCR-T Products — Duarte, California
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) — Sacramento, California
- Cardioprotection in AML — Charlottesville, Virginia
- UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — Birmingham, Alabama
Explore by condition: All AML clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.